RT Journal Article
SR Electronic
T1 A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.28.22270035
DO 10.1101/2022.01.28.22270035
A1 Chupp, Geoffrey
A1 Spichler-Moffarah, Anne
A1 Søgaard, Ole S.
A1 Esserman, Denise
A1 Dziura, James
A1 Danzig, Lisa
A1 Chaurasia, Reetika
A1 Patra, Kailash P.
A1 Salovey, Aryeh
A1 Nunez, Angela
A1 May, Jeanine
A1 Astorino, Lauren
A1 Patel, Amisha
A1 Halene, Stephanie
A1 Wang, Jianhui
A1 Hui, Pei
A1 Patel., Prashant
A1 Lu, Jing
A1 Li, Fangyong
A1 Gan, Geliang
A1 Parziale, Stephen
A1 Katsovich, Lily
A1 Desir, Gary V.
A1 Vinetz, Joseph M.
YR 2022
UL http://medrxiv.org/content/early/2022/01/31/2022.01.28.22270035.abstract
AB Importance Early treatment of mild SARS-CoV-2 infection might lower the risk of clinical deterioration in COVID-19.Objective To determine whether oral camostat mesylate would reduce upper respiratory SARS-CoV-2 viral load in newly diagnosed outpatients with mild COVID-19, and would lead to improvement in COVID-19 symptoms.Design From June, 2020 to April, 2021, we conducted a randomized, double-blind, placebo-controlled phase 2 trial.Setting Single site, academic medical center, outpatient setting in Connecticut, USA.Participants Of 568 COVID-19 positive potential adult participants diagnosed within 3 days of study entry and assessed for eligibility, 70 were randomized and 498 were excluded (198 did not meet eligibility criteria, 37 were not interested, 265 were excluded for unknown or other reasons). The primary inclusion criteria were a positive SARS-CoV-2 nucleic acid amplification result in adults within 3 days of screening regardless of COVID-19 symptoms.Intervention Treatment was 7 days of oral camostat mesylate, 200 mg po four times a day, or placebo.Main Outcomes and Measures The primary outcome was reduction of 4-day log10 nasopharyngeal swab viral load by 0.5 log10 compared to placebo. The main prespecified secondary outcome was reduction in symptom scores as measured by a quantitative Likert scale instrument, Flu-PRO-Plus modified to measure changes in smell/taste measured using FLU-PRO-Plus.Results Participants receiving camostat had statistically significant lower quantitative symptom scores (FLU-Pro-Plus) at day 6, accelerated overall symptom resolution and notably improved taste/smell, and fatigue beginning at onset of intervention in the camostat mesylate group compared to placebo. Intention-to-treat analysis demonstrated that camostat mesylate was not associated with a reduction in 4-day log10 NP viral load compared to placebo.Conclusions and relevance The camostat group had more rapid resolution of COVID-19 symptoms and amelioration of the loss of taste and smell. Camostat compared to placebo was not associated with reduction in nasopharyngeal SARS-COV-2 viral load. Additional clinical trials are warranted to validate the role of camostat mesylate on SARS-CoV-2 infection in the treatment of mild COVID-19.Trial registration: Clinicaltrials.gov, NCT04353284 (04/20/20) (https://clinicaltrials.gov/ct2/show/NCT04353284?term=camostat+%2C+yale&draw=2&rank=1)Question Will early treatment of COVID-19 with a repurposed medication, camostat mesylate, improve clinical outcomes?Findings In this phase 2 randomized, double-blind placebo-controlled clinical trial that included 70 adults with early COVID-19, the oral administration of camostat mesylate treatment within 3 days of diagnosis prevented the loss of smell/taste and reduced the duration of illness.Meaning In the current COVID-19 pandemic, phase III testing of an inexpensive, repurposed drug for early COVID-19 is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04353284Funding StatementThis investigator-initiated study was supported by Kenneth C. Griffin, the Prostate Cancer Foundation, the COVID-19 Early Treatment Fund, and the Harrington Discovery Institute, institutional funds from the Department of Internal Medicine at the Yale School of Medicine, and the Yale Center for Clinical Investigation. This study was partially supported by the United State Public Health Service grant, 5UL1RR024139. Ono Pharmaceuticals provided the study drug, FOIPAN, at no cost to the study but had no input into study design or the writing or content of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Yale University Human Subjects Protection Program/IRB approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors